SCYX SCYNEXIS INC

SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event

SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event

JERSEY CITY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer, will participate in a panel discussion during Maxim Group LLC’s Late Stage Innovations in Women’s Health event, which is part of the M-Vest Virtual Conference series. The virtual event will take place at 11:00 am Eastern Time on March 4, 2021.

The panel will be moderated by Jason McCarthy, PhD, Senior Managing Director and Head of Biotechnology Research – Equity Research at Maxim Group.

During the panel discussion, Dr. Taglietti will share insight on Brexafemme, an oral antifungal product candidate under review by the U.S. Food and Drug Administration (FDA) for the treatment of vaginal yeast infection, also known as vulvovaginal candidiasis (VVC), with a Prescription Drug User Fee Act (PDUFA) action date of June 1, 2021.

For additional information on the event and to register, please click .

About SCYNEXIS



SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat fungal infections that are becoming increasingly drug-resistant. Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, that is in FDA review for the treatment of vaginal yeast infection and late-stage clinical development for multiple life-threatening fungal infections in hospitalized patients. The  has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. For more information, visit .

CONTACT: 

Investor Relations

Irina Koffler

LifeSci Advisors

Tel: (646) 970-4681

Media Relations

Gloria Gasaatura

LifeSci Communications

Tel: (646) 970-4688



EN
25/02/2021

Underlying

SCYXSCYNEXIS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCYNEXIS INC

 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Announces Multiple Presentations Highlighting Data from its S...

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations highlight SCY-247’s broad spectrum of antifungal activity, against Candida species, including multidrug- and pandrug-resistant C. auris and Aspergillus speciesCompany anticipates reporting Phase 1 Single Ascending D...

September 4, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conf...

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025 JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior leadership team will participate in the H.C. Wainwright 27th Annual Global Conference. Date: Wednesday September 10, 2025Format: In-person presentation and 1x1 meetingsTime: 10:30 a.m.-11:00 a.m. ETLocation: New York, NY If you are intere...

August 25, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Co...

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments.  SCYNEXIS vigorously disagrees with GSK’s position and is working towards resolving this disagreement; SCYNEXIS is actively working with GSK to transfer the BREXAFEMME New Drug Application (NDA) to G...

August 13, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and SCYNEXIS vigorously disagrees with their position JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant i...

May 28, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Cor...

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh recently received Chinese (NMPA) approval for ibrexafungerp in the treatment of acute VVC. SCYNEXIS will receive a milestone payment from Hansoh upon commercialization as well as royalties of approximately 10% on China sales.Presented positive preclinical data for its second-generation fungerp candidate...

May 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch